Ranger Investment Management L.P. Invests $14.23 Million in Medpace Holdings, Inc. $MEDP

Ranger Investment Management L.P. purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, Holdings Channel reports. The fund purchased 26,869 shares of the company’s stock, valued at approximately $14,230,000.

Other institutional investors also recently added to or reduced their stakes in the company. BOKF NA increased its holdings in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after acquiring an additional 21 shares during the last quarter. UMB Bank n.a. boosted its stake in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after acquiring an additional 24 shares during the last quarter. Schulhoff & Co. Inc. grew its position in shares of Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after acquiring an additional 25 shares during the period. Finally, Balefire LLC grew its position in shares of Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after acquiring an additional 26 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

MEDP opened at $620.75 on Monday. The firm has a 50-day moving average price of $550.16 and a 200-day moving average price of $492.03. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares in the company, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the transaction, the director owned 3,798 shares of the company’s stock, valued at $2,302,157.70. This trade represents a 65.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 122,261 shares of company stock worth $71,729,129 in the last three months. 20.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Robert W. Baird lifted their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. BMO Capital Markets raised their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Barclays set a $600.00 target price on Medpace in a research note on Thursday, July 23rd. Truist Financial upped their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Mizuho increased their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.